Interestingly, when characterising CTCs according to the presence of AR, we found that 100% of patients with AR-positive CTCs were EGFR-negative in the prostate cancer tissue, whereas up to 75% of patients with AR-negative CTCs presented EGFR-positive tissue (p= 0.5). The gene discussed is EGFR; the disease is prostate carcinoma.